GSK-controlled drug firm working on version of jab to be administered by patient at home by end of decade
One of the world’s largest commercial developers of HIV drugs is working on a treatment that can be injected by patients at home every two to three months by the end of the decade, saving them frequent visits to the clinic.
ViiV Healthcare, a GlaxoSmithKline-controlled joint venture, makes 17 prescription HIV medicines, including the long-acting treatment cabotegravir, which was first approved in the US in January 2021.
